BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Veloxis Pharmaceuticals A/S 

Kogle Allé 4

  DK-2970  Hørsholm  Denmark
Phone: 457-033-3300 Fax:


SEARCH JOBS




Industry
Pharmaceutical






 Company News
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014 8:32:36 AM
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014 8:06:09 AM
Veloxis Pharmaceuticals A/S (VELO) Announces Positive Two-Year Results From Pivotal Phase 3 Study Of Envarsus® XR (Tacrolimus Extended-Release Tablets) In De Novo Kidney Transplant Patients 6/23/2014 10:50:42 AM
Veloxis Pharmaceuticals A/S (VELO) Announces Senior Level Appointments In Preparation For U.S. Commercialization Of Envarsus® XR (Tacrolimus Extended-Release Tablets) 6/4/2014 9:05:48 AM
Veloxis Pharmaceuticals A/S (VELO) Receives Positive Opinion From CHMP For Envarsus® For Treatment Of Both Kidney And Liver Transplant Patients 5/22/2014 9:25:27 AM
Veloxis Pharmaceuticals A/S (VELO) Release: Warrant Programme - New Articles Of Association 5/22/2014 9:23:04 AM
Veloxis Pharmaceuticals A/S (VELO) Announces Financial Results For The First Three Months Of 2014 5/15/2014 6:18:41 AM
Veloxis Pharmaceuticals A/S (VELO) Announces Financial Results For The First Three Months Of 2014 5/14/2014 11:21:58 AM
Veloxis Pharmaceuticals A/S (VELO) To Host Conference Call Announcing Interim Report For First Quarter 2014 – Results From 1 January To 31 March, 2014 5/6/2014 9:17:37 AM
Veloxis Pharmaceuticals A/S (VELO) Announces Scientific Publication Of Phase 2 Study Demonstrating Conversion From Twice-Daily Tacrolimus To Once-Daily Envarsus® In Liver Transplant Patients 4/28/2014 9:39:04 AM
1234567